AZN Stock Chart & Fundamental Analysis

Interactive Chart

About AstraZeneca PLC

Name

AstraZeneca PLC

CEO

Pascal Claude Roland Soriot

Website

www.astrazeneca.com

Industry

Healthcare

Year Founded

1992

Employees

96,100

AstraZeneca PLC develops and sells prescription medicines as a large pharmaceutical company listed on the NYSE under AZN, spanning discovery, development, manufacturing, and commercialization. Its portfolio generated $58.7 billion in FY2025 revenue across treatments for cancer, cardiovascular, renal and metabolic conditions, COVID-19, and rare diseases.

Analyst Ratings

Consensus Recommendation

Buy1

Hold1

Sell5

Fundamentals & Financials

Revenue (TTM)

$60.4B

Net Income (TTM)

$10.3B

EPS (TTM)

$13.42

ROA (TTM)

9.17%

Current Ratio

0.91

Dividend Yield

2.15%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Item	Q1 FY2026	Q4 FY2025	Q3 FY2025
Revenue	$15,288M	$15,503M	$15,191M
Cost of Sales	$2,678M	$3,118M	$2,801M
Gross Profit	$12,610M	$12,385M	$12,390M
Operating Income	$4,246M	$2,978M	$3,583M
Net Income	$3,080M	$2,326M	$2,533M
EPS	$3.98	$3.02	$3.26

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings Calendar

Technical Indicators

AstraZeneca PLC's Technical Indicators Summary

AZN exhibits a predominantly negative technical profile, with price trading beneath most medium- and long-term moving averages and momentum indicators tilted downside, including a negative MACD. Trend strength is moderate but not strong, and OBV indicates net selling pressure while ATR shows only moderate volatility. A few short-term oscillators have begun to flash oversold/buy signals, however the broader alignment of moving averages and momentum favors the bearish conclusion. Technical takeaway: Strong Sell.

Buy

1 signal

Neutral

1 signal

Sell

5 signals

Overall: Bearish71% Bearish signals

Indicator	Value	Signal	Explanation
RSI (14)	42.03	Neutral	RSI (42.03) is neutral.
Stochastic %K (14, 3, 3)	16.39	Buy	Stochastic (16.39) < 20, indicating oversold.
CCI (20)	-55.61	Neutral	CCI (-55.61) is neutral.
WPR (14)	-82.51	Buy	Williams %R (-82.51) < -80, indicating oversold.
Momentum (10)	-2.35	Sell	Momentum (-2.35) is negative.
MFI	33.46	Neutral	MFI (33.46) is neutral.
MACD Level (12, 26)	-4.29	Sell	Confirmed downtrend: MACD (-4.29) is negative and below its signal line (-3.59).
Bollinger Bands	$155.69 - $199.54	Neutral	Price is within the bands.
ATR (14)	$4.66 (2.75%)	Neutral	Moderate Volatility (2.75%).
ADX (14)	23.12	Neutral	Weak or consolidating trend (ADX < 25). ADX(23.12), +DI(20.18), -DI(35.26)
OBV	13,976,882	Sell	Bearish volume pressure: OBV is below its 20-day SMA. OBV(13,976,882), 20D-SMA-OBV(19,910,473)
Classic Pivot Point	$167.93	Neutral	Price ($169.26) is above the pivot ($167.93) but not yet breaking resistance R1 ($169.83) — mildly bullish / neutral zone.
Fibonacci Pivot Point	$167.93	Buy	Price ($169.26) has broken above resistance R1 ($169.25) — bullish breakout potential.
Simple Moving Averages	$168.16 - $186.70(5 indicators)	Sell	SMA group: 4/5 bearish, 1 bullish, 0 neutral. Price below key SMA averages.
Exponential Moving Averages	$170.53 - $182.65(5 indicators)	Sell	EMA group: 5/5 bearish, 0 bullish, 0 neutral. Price below key EMA averages.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

Into the close, AZN retained a slight positive bias, with a 0.44% gap from yesterday. The day closed with AZN still facing an upcoming earnings catalyst in 3 days on 27 July. AZN faces a rare trial failure, potentially triggering a share slide and added volatility.

Trading Volume

Below 10d avg (2.7M)

1.8M

vs S&P 500 Today

Outperforming Market

+0.53%

52-Week Position

Mid-range

37.3%

Updated: July 24, 2026 at 20:04 UTC